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 A 67-year-old woman with essential thrombocythemia (ET) 
developed acute heart failure and marked pulmonary hy-
pertension (PH). No clear cause for the PH could be initially 
found. We suspected that thrombocytosis might cause PH. 
Treatments with anticoagulant (heparin and warfarin), plate-
let-lowering (hydroxyurea), and antiplatelet (ticlopidine) agents 
resulted in improvement of the clinical, hemodynamic con-
ditions, and the control of platelet counts. We found that 
the main etiology of PH in the present case might be the 
pulmonary capillary obstruction from local pulmonary 
microthrombosis complicated with ET. Although PH associ-
ated with ET is uncommon, it should be always considered 
as a possible cause of dyspnea in patients with ET. 
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hypertension (PH). Although the possible association 
of PH with CMPD has been suggested by some case 
reports and clinical studies,'-"' their etiology and treat-
ment have been controversial. We report a case of se-
vere PH developing coincidence with remarkable 
thrombocytosis. The PH might be possibly caused by 
local microthrombosis in pulmonary arteries (PA).
Case Report
Introduction
 Essential thrombocythemia (ET) is a chronic mye-
loproliferative disorder (CMPD) characterized by eleva-
tion of platelet count, which results from clonal prolif-
eration of a single neoplastic multipotent stem cell, 
affecting primarily megakaryocyte production."" ET is 
often associated with hemostatic complications, both 
thrombotic and hemorrhagic. Thromboembolic compli-
cations are the main cause of morbidity and mortality in 
ET, especially cerebral, myocardial, and peripheral ar-
terial thrombosis."') However, isolated pulmonary com-
plications are infrequent in the CMPD. Thrombocytosis 
in the absence of thromboembolic disease has only 
rarely been suspected as the etiology of pulmonary
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 A 67-year-old woman was admitted to our hospital 
with complaint of exertional dyspnea (NYHA grade 
III). The dyspnea had been present for about one 
week, with the symptoms gradually worsening before 
admission. She 1-lad a history of hypertension of un-
known duration. Seven years before current admission 
she had been diagnosed as ET, but she had no ade-
quate therapy for ET since diagnosed. On physical ex-
amination, she was 150 cm tall and weighed 52 kg, 
the body temperature was 36.8°C, blood pressure was 
140/108 mmHg with a regular pulse of 102 beats/-
min, and respiratory rate was 24 cycles/min. A grade 
3/6 systolic murmur was heard at the left sternal bor-
der with the second intercostal space, but breathing 
sound was almost normal. There was edema of the 
face and upper and lower extremities. Arterial blood 
gas analysis showed Pa02 44 mmHg, PaCO2 30.5 
mmHg, pH 7.43 and HCO3- 20.6 mEq/1 while breathing 
14 liters 02 through a facemask. Chest X-ray showed 
cardiomegaly (cardiothoracic ratio, 65%), enlargement 
of the proximal parts of PA bilaterally (Figure 1). An 
electrocardiogram revealed regular sinus rhythm at a 
rate of 105 beats/min, right axis deviation, clockwise 
rotation (with deep S wave in leads V5 and V6), S 
wave in lead I, Q wave in lead III, and inverted T 
wave in leads III, V1-V4 (Figure 1). Transthoracic echo-
cardiography revealed enlarged right ventricle (RV) 
with flattening of the interventricular septum at end-
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diastole in parasternal short-axis view. Doppler echo-
cardiography revealed severe regurgitation of the tri-
cuspid valve and the estimated pressure gradient be-
tween RV and right atrium (RA) was 68.5 mmHg. M-
mode parameters of left ventricle are summarized in 
Table 1.
Figure 1. Chest X-ray and electrocardiogram (10mm=lmV) 
on admission.
Table 1. M-mode and Doppler Measurements by Echocardiagraphy
               Day 1 Day 4 Day 24 
IVS (mm) 12.8 11.7 11.1 
PW (mm) 11.8 11.8 11.5 
LVDd (mm) 35.7 41.9 43.4 
LVDs (mm) 19.8 25.8 27.6 
EDV (ml) 53.3 74 82 
ESV (ml) 12.4 17 21 
SV (ml) 40 56 61 
EF (%) 77 77 75 
RV-RA PG (mmHg) 68.5 47.7 19.2
IVS=interventricular septum. PW=left ventricular posterior wall. LVDd=left ventricular end-
diastolic dimension. LVDs=left ventricular end-systolic dimension. LVEDV=left ventricular end-
diastolic volume. LVESV=left ventricular end-systolic volume. SV=stroke volume. LVEF=left 
ventricular ejection fraction (by Teichholz method). FS=fractional shortening. RV-RA PG=pressure 
gradient between right ventricle and right atrium.
Table 2. Laboratory Findings on Admission
Hematology 
RBC 400 X 104 /mm3 
Hgb 13.1 g/dl 
Hct 38.9% 
WBC 10900 / mm3 
Pit 102 X 104 / mm3 
Blood Chemistry 
TP 7.3 g/dl 
T-Bil 0.95 mg/dl 
GOT 20 U/1 
GPT 20 U/1 
LDH 261 U/1 
CPK 73 mU/dl 
T.chol 172 mg/dl 
TG 50 mg/dl 
BUN 12.2 mg/dl 
Cr 0.64 mg/dl 
Na 140 mEq/1 
K 3.7 mEq/1 
CI 107 mEq/1 
Coagulation and Fibrinolysis tests 
Fibrinogen 396 mg/dl 
PT 57.7% 
APTT 31.4 sec 
FDP 25.6 g/ml 
ATIII 70% 
D dimmer 17.6 tt g/ml 
Serological tests 
CRP 2.80 mg/dl
 Laboratory findings are summarized in Table 2. There 
were leukocytosis and remarkable thrombocytosis. Bio-
chemical findings included slightly increased lactate 
dehydrogenase (LDH) and C-reactive protein (CRP) lev-
els. Coagulation and fibrinolysis tests showed high levels 
of fibrin degeneration products (FDP) and D-dimer, and 
low prothrombin time (PT) and low levels of antithrombin-
III (AT-III). Whereas, the other data, such as activated 
partial thromboplastin time (APTT), fibrinogen, protein 
C and protein S, were within normal limits. Both anti-
cardiolipin antibodies and lupus anticoagulant were 
negative. 
 Based on these findings, we initially suspected acute 
pulmonary thromboembolism (APTE) as a cause of 
dyspnea, and performed further examinations. A chest 
enhanced computed tomography (CT) revealed
enlargement of RA, RV, and proximal part of PA 
without definite signs of thrombi in PA. In addition, 
chest CT revealed mild pericardial and pleural effu-
sion, and mild congestion in the bilateral lung fields. 
Enhanced CT of abdomen, pelvis, and lower extremities 
were also performed, which revealed no signs of ve-
nous thrombosis. Lung perfusion scintigram revealed 
some defects in the right upper and left lower lung 
fields (Figure 2). Pulmonary angiography (PAG) showed 
small filling defects in segmental branches of the right 
superior and left inferior PA (Figure 3). Right heart 
catheterization revealed highly elevated pulmonary ar-
terial pressure (PAP; systolic/diastolic/mean: 81/32/52 
mmHg) (Table 3). 
 Symptomatic treatment for right sided heart failure 
due to PH was instituted with diuretics, and the dose







Figure 2. Lung perfusion scintigram on admission (before 
treatment) and at 29 days after treatment. Note the improve-








of diuretics was increased because chest CT revealed 
mild increment of pericardial and pleural effusion on 
the 7th days after admission. Suspecting the possibility 
of APTE, intravenous urokinase (24X10' U/day for 7 
days) and heparin (10,000 U/day) therapy were com-
menced from the day of admission. APTT remained 
within normal limits despite increment of heparin 
(10,000 to 20,000 U/day), which seemed to be due to 
low AT-III. Accordingly, we commenced intravenous 
administration of AT-III (2,000 U/day for 3 days). 
Heparin was replaced with warfarin from 7 days after 
admission at a dose of 3.5 to 4.0 mg/day, which was 
adjusted to maintain an international normalized ratio 
(INR) of 1.5 to 2.5. 
 Platelet counts gradually increased from 102X 104/mm3 
on admission to a maximum of 151 X 104 /mm3 on 
the 21st day after admission (Figure 4). Platelet func-
tion tests of peripheral venous blood were performed 
in vitro, which demonstrated normal platelet aggrega-
tion in response to ADP and collagen, and normal plate-
let activation in expression of p-selectin (CD62) on 
the platelet surface. Bone marrow aspiration showed 
hypermegakaryocytosis with normocellularity but no 
signs of malignancy. We diagnosed this patient as ET 
according to the criteria of Polycythemia Vera Study 
Group (PVSG).13' To reduce the platelet count, ranimustine 
was administered intravenously at a dose of 100 mg/-
day on 8th and 15th days after admission. In addition, 
oral administration of hydroxyurea was commenced at 
a dose of 1000 mg/day from 21st day after admission, 
and the dose was adjusted based on platelet count. 
Finally, ticlopidine (100mg twice per day) was com-
bined with warfarin and hydroxyurea.
Figure 3. Right (Rt) and left (Lt) pulmonary angiography on 
admission and 36 days after treatment. Note small filling de-
fects in segmental branches of the right superior and left in-
ferior pulmonary artery (arrows). No clear filling defects are 
detected on 36 days after treatment.
Table 3. Right Heart Catheterization
                       Day 1 Day 7 Day 36 
mRAP (mmHg) 9 2 1 
RVP(mmHg) 81/1 52/-2 35/-2 
RVEDP(mmHg) 16 6 4 
PAP (mmHg) 81/32 55/20 36/15 
mPAP (mmHg) 52 31 23 
mPCWP (mmHg) 8 14 1 
Cardiac Output (L/min) 4.45 4.31 
Cardiac Index (L/min/m2) 2.92 2.89
mRAP=mean right atrial pressure. RVP=right ventricular pressure. RVEDP=right ventricular end-
diastolic pressure. PAP=pulmonary arterial pressure. mPAP=mean PAP. mPCWP=mean pulmonary 
capillary wedged pressure.
Figure 4. The change of platelet count during hospitaliza-
tion.
 The patient subsequently had a good response to 
these treatments with fall in her platelets counts, clini-
cal improvement in right heart failure, and decrement 
in PAP to 55/20 (mean 31) mmHg and 36/15 (mean
23) mmHg on 7th and 36th days after admission 
(Table 3). PAG showed no clear filling defects on 36th 
days after admission (Figure 3). However, lung perfu-
sion scintigram revealed persistence of slight defects 
on 29th day after admission (Figure 2). Furthermore, 
hypoxemia (Pa02 60 mmHg and PaCO2 37.6 mmHg; room 
air) persisted without complaint of dyspnea. 
 After discharge from the hospital, the patient had no 
evidence of right heart failure, and her oxygen satura-
tion was improving and she was almost asymptomatic. 
The platelet count was kept within normal limits.
Discussion
  In the present case, we found that the main predis-
posing factor for pulmonary thrombosis was ET, be-
cause our patient had no corroborating clinical history 
and clear radiological findings indicating deep venous 
thrombi as an origin of pulmonary thrombosis. In ad-
dition, our patient had no other predisposing factors 
for venous thrombosis, such as collagen diseases, 
nephrotic syndrome, diabetes mellitus, malignant dis-
eases, or the use of oral contraceptive agents. 
 The possible association of PH with CMPD, such as 
ET, polycythemia vera, and myelofibrosis with mye-
loid metaplasia, has been suggested by some case re-
ports and clinical studies.'-"' Reisner et al reported 
that PH was demonstrated in 13% of patients with 
CMPD by Doppler echocardiography." `Jdith regard to 
the etiology of PH, CMPD can elevate PAP by various 
potential mechanisms. It is generally accepted that 
megakaryocytes (10 to 150,1) continually migrate from 
the bone marrow and are trapped within the pulmo-
nary capillaries (7 to 10,1 in diameter) where transfor-
mation to platelets normally occurs.'' Megakaryocytes 
have been demonstrated to be plentiful in the pulmo-
nary capillary bed.") Marvin et al postulated the direct 
pulmonary capillary obstruction by megakaryocytes with 
stasis and secondary micro thrombosis." On the other 
hand, some previous studies have demonstrated the local 
pulmonary platelet activation and the increased me-
tabolism of prothrombin and fibrinogen in patients with 
ET.'' 16' In addition, it has been reported that platelet-
derived growth factor released from activated platelets 
is a strong stimulus for smooth muscle hyperplasia.l" 
By these mechanisms, ET can possibly introduce micro-
thrombosis in the pulmonary circulation and elevate 
PAP. 
 We speculate that the following mechanisms of PH 
can be possibly applied to the present case. Firstly, chronic 
silent pulmonary microthrombosis may have existed 
subclinically without apparent subjective symptoms in
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the past, and have already been organized in part. The 
present case may be not acute onset but rapid deterio-
ration of subclinical PH. We suspect that this mechanism 
may lead to her tolerance for high level of hypoxemia 
and PH on admission without severe dyspnea and 
hemodynamical shock. Secondly, we suspect that not 
only pulmonary thrombosis but also mild volume over-
load, which was indicated by mild increment of peri-
cardial and pleural effusion and elevated pulmonary 
capillary wedged pressure could contribute to PH to some 
degree. Thirdly, we cannot completely deny a possibil-
ity that complicated pulmonary thromboembolism, which 
arose from unknown origin of venous thrombi, could 
contribute to PH in acute phase. 
 Recommended treatments for PH in patients with 
thrombocytosis have varied from report to report and 
have been controversial: anticoagulant, antiplatelet and/ 
or platelet-lowering therapy have been shown to be 
beneficial.57810 112) Our patient showed good responses 
to the combination of these treatments. However, there 
is a possibility that thrombolytic and anticoagulant 
therapy alone might be able to result in gradual fall 
in PAP even if not combined with antiplatelet and 
platelet-lowering therapy. This possibility is indicated 
by the finding that PAP decreased despite the further 
increase of platelet counts in acute phase. In addition, 
we speculate that the persistence of hypoxemia and 
slight defects in lung perfusion scintigram in chronic 
phase was probably due to residual organized micro-
thrombi of peripheral PA, for which these treatments 
were not effective. 
 Except pulmonary thrombosis, our patient seemed 
not to have other major thrombotic complications such 
as stroke, myocardial infarction, and peripheral arte-
rial thrombosis because she did not present subjective 
symptoms nor radiological findings to indicate these 
thrombotic complications. Although we could not per-
form coronary angiography because of patient's rejec-
tion, she did not demonstrate such findings to indicate 
myocardial infarction as the elevation of cardiac en-
zymes or the asynergy of left ventricular wall motion 
by echocardiography. 
 In conclusion, we reported a case of PH in a patient 
with ET. We suspected the chronic silent micro-
thrombosis in local PA as etiology of PH. Treatments 
with anticoagulant, platelet-lowering, and antiplatelet 
agents were effective for controlling platelet counts and 
PAP. Although PH associated with ET is uncommon, 
it should be always considered as a possible cause of 
dyspnea in patients with ET.
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